Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?

Key Takeaways Keytruda sales rose 7% to nearly $31.7B in 2025, driving about 55% of MRK's pharma sales.Keytruda growth is fueled by earlier-stage uptake, metastatic indications and Keytruda Qlex launch.MRK projects more than $70B in pipeline opportunities by mid-2030s beyond the Keytruda LOE.Merck (MRK) has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s pharmaceutical sales and has ...